SCHEMBL4768474

SCHEMBL4768474

CC(C)OC(=O)N1CCCC(=O)c2nc(Cl)ccc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
IDO1 P14902 9/20 0.36
KCNH2 Q12809 4/20 0.36
KMT2A Q03164 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
SRD5A1 P18405 1/20 0.34
INSR P06213 1/20 0.34
MET P08581 1/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
SLC6A15 Q9H2J7 1/20 0.33
SCN9A Q15858 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
NOTUM Q6P988 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773023 0.84 KDM4E (0.39) KDM4EIDO1KCNH2KMT2ACYP3A4
SCHEMBL4774567 0.80 KDM4E (0.34) KDM4EIDO1KCNH2KMT2ACYP2C9
SCHEMBL4774766 0.80 ALDH1A1 (0.35) KDM4EKMT2AALDH1A1HPGDTSHR
SCHEMBL4768298 0.78 SMN1; SMN2 (0.35) KDM4EIDO1KCNH2KMT2AINSR
SCHEMBL3532281 0.75 SLC6A15 (0.41) KDM4EIDO1KMT2AALDH1A1HPGD
SCHEMBL4765266 0.75 HTR2C (0.35) KDM4EIDO1KCNH2KMT2ACYP2C9
SCHEMBL3535539 0.74 NOTUM (0.48) KMT2ACYP2C9ALDH1A1LMNAHPGD
SCHEMBL2475561 0.72 ABHD6 (0.46) KDM4EKMT2ASRD5A1ALDH1A1LMNA
SCHEMBL3537930 0.72 MEN1 (0.42) KDM4EKMT2AALDH1A1LMNAHPGD
SCHEMBL3529510 0.72 L3MBTL1 (0.40) KDM4EIDO1KCNH2KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732933-B1 COMPOUNDS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2008-07-23 EP disclosed
EP-1732933-B1 COMPOUNDS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2008-07-23 EP disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
EP-1732933-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-12-20 EP disclosed
WO-2005097805-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA PCSK9, LIPC, APOB KDM4E 1101/4885IDO1 4375/4885KCNH2 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.